HistoIndex Receives Frost & Sullivan 2017 Asia-Pacific Best Practices Award
Dr Gideon Ho, CEO of HistoIndex, receiving the award from Ms Rhenu Bhuller, a Partner & SVP at Transformational Health, Frost & Sullivan. (Photo Credits – HistoIndex & Frost & Sullivan)
5 Oct 2017 - Histoindex Pte. Ltd. has been presented with the 2017 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Diagnostics New Product Innovation Award by Frost & Sullivan. The award is a testament of the achievements by HistoIndex and the impact of its proprietary technologies on aiding clinical diagnosis and the development of NASH therapeutics.
Labelled as a silent disease, NASH is a more severe form of non-alcoholic fatty liver disease (NAFLD), and wreaks havoc in the livers of patients, even in those who only encounter minimal symptoms. In Asia, 15-30 per cent of the general adult population suffers from NAFLD.
With obesity and diabetes reaching epidemic figures, NASH is projected to overtake Hepatitis C as the biggest cause of liver transplants by 2020. There are currently no FDA-approved drugs for NASH, and the major markets for NASH drugs are currently estimated to reach US$49 billion by 20274. State-of-the-art imaging technologies such as the Genesis®200 by HistoIndex can greatly facilitate the development of precise and effective therapeutics for this huge unmet need.
Congratulations to A*STAR spinoff HistoIndex and Dr Gideon Ho, for yet another milestone achieved!
Refer to Histoindex News Release for full article.